Shanghai, China

Qingyun Jiang

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 12.3

ph-index = 1


Company Filing History:


Years Active: 2021-2025

where 'Filed Patents' based on already Granted Patents

3 patents (USPTO):

Qingyun Jiang: Innovator in Medicinal Chemistry

Introduction

Qingyun Jiang is a prominent inventor based in Shanghai, China, recognized for his significant contributions to the field of medicinal chemistry. With two patents to his name, his innovations are poised to make a substantial impact on medical science and therapeutics.

Latest Patents

Qingyun Jiang's latest patents include a class of µ-opioid receptor agonists, along with their preparation methods and applications in the medical field. These agonists increase the selectivity for a G protein signaling pathway, demonstrating excellent pharmacodynamic effects while significantly enhancing safety.

His second patent focuses on a pyrido five-element aromatic ring compound, detailing its preparation method and uses. This compound exhibits an inhibitory effect on wild-type and/or mutant EZH2, earmarking it as a promising candidate for a novel anti-tumor drug or a treatment for autoimmune diseases.

Career Highlights

Throughout his career, Qingyun Jiang has worked with notable companies in the pharmaceutical field, including Shanghai Synergy Pharmaceutical Sciences Co., Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. His expertise in medicinal chemistry and innovative approach has positioned him as a valuable asset in the industry.

Collaborations

In his journey as an inventor, Qingyun has collaborated with colleagues such as Xin Xu and Zhen Zhang, bringing together diverse expertise that has enhanced his research and innovations in the pharmaceutical domain.

Conclusion

Qingyun Jiang continues to lead the way in medicinal chemistry with his groundbreaking inventions. His work on µ-opioid receptor agonists and pyrido five-element aromatic ring compounds demonstrates a commitment to improving drug safety and efficacy, promising new therapeutic solutions for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…